Homelessness and Prevalence of Neurodevelopmental Disorders
PRECA'TND
Prevalence of Neurodevelopmental Disorders in a Homeless Population - Pilot Study
1 other identifier
interventional
150
1 country
1
Brief Summary
Introduction \& Central question: Psychiatric disorders are highly prevalent in the homeless population, however neurodevelopmental disorders are also at risk of leading to homelessness (Churchard et al., 2018; Casey et al., 2020). Research on this topic is poor in France. This research aims to study the prevalence in France of 3 neurodevelopmental disorders (NDDs) in a homeless population (Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Intellectual Developmental Disorder). Methods / approach: A 2 phase approach will be used including a screening phase and a diagnosis phase. This research is a pilot study that will include 150 homeless people, over 2 years. The assessment involves combining the results from standardised self-report tools, direct observation and informant-report, thus guaranteeing an objective and thorough diagnosis. This approach gives a better picture of actual behaviour but also a better understanding of the person's development. OUTCOME: This study will give insight on how to better understand the profile of the homeless population in France, and the prevalence of autism in this population. It will also bring valuable knowledge on how autism and other NDDs can impact one's path in life and lead to homelessness. The results can help develop targeted cares and measures for homeless people with NDDs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 5, 2025
CompletedFirst Posted
Study publicly available on registry
March 11, 2025
CompletedStudy Start
First participant enrolled
September 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2027
August 1, 2025
July 1, 2025
1.5 years
March 5, 2025
July 29, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prevalence (percentage) of ASD, ADHD and IDD in the studied population (homeless people sheltered in accommodation and social rehabilitation centers).
For each NDD here are the scores and tools used : ASD : * AQ-10 cut-off score * CAT-Q cut-off score(Camouflage of Autistic Traits Questionnaire) * Glasgow questionnaire : standard score deviations * DATHi (DSM-5 Autistic Traits in the Homeless Interview) : cut-off score ADHD: * ADHD Self-report (ASRS) : cut-off score * Diagnostic Interview for Adult ADHD (DUVA-5): cut-off score * ASRS - Observer : cut-off score IDD: * Raven matrices: score * Vineland Adaptive Behaviour Scale (2nd edition): cut-off score
4 months
Secondary Outcomes (5)
Demographic information
4 months
Judicial information
4 months
Medical Record
4 months
Drug abuse
4 months
History of traumatic brain injury, epilepsy and coma
4 months
Study Arms (1)
Homeless people sheltered in accommodation and social rehabilitation centers
OTHERPrevalence (percentage) of ASD, ADHD and IDD in the studied population (homeless people sheltered in accommodation and social rehabilitation centers).
Interventions
This study is an observational prospective multi-centric non interventional study. The focus of the study is a homeless population sheltered in accommodation and social rehabilitation centres. The prevalence of neurodevelopmental disorders in this population will be studied.
Eligibility Criteria
You may qualify if:
- Homeless people sheltered in accommodation and social rehabilitation centers
- Over 18 years of age
- Who speak French
- who have given then written informed consent
You may not qualify if:
- \- Every person who hasn't given their written informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hopital Vinatier
Lyon, Auvergne-Rhône-Alpes, 69678, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Caroline DEMILY, MdPh
VINATIER HOSPITAL
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 5, 2025
First Posted
March 11, 2025
Study Start
September 15, 2025
Primary Completion (Estimated)
April 1, 2027
Study Completion (Estimated)
September 30, 2027
Last Updated
August 1, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share